Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
3.310
-0.050 (-1.49%)
Jun 25, 2025, 4:00 PM - Market closed
Puma Biotechnology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 232.71 | 230.47 | 235.64 | 228.03 | 253.16 | 225.11 | Upgrade
|
| Revenue Growth (YoY) | 2.68% | -2.19% | 3.34% | -9.92% | 12.46% | -17.32% | Upgrade
|
| Cost of Revenue | 64.23 | 64.4 | 62.68 | 55.09 | 63.7 | 39.37 | Upgrade
|
| Gross Profit | 168.48 | 166.06 | 172.96 | 172.94 | 189.45 | 185.74 | Upgrade
|
| Selling, General & Admin | 76.02 | 80.16 | 89.31 | 89.98 | 116.29 | 118.49 | Upgrade
|
| Research & Development | 55.21 | 54.94 | 50.38 | 52.24 | 71.87 | 97.65 | Upgrade
|
| Operating Expenses | 131.23 | 135.1 | 139.69 | 142.22 | 188.16 | 216.14 | Upgrade
|
| Operating Income | 37.25 | 30.97 | 33.27 | 30.72 | 1.29 | -30.4 | Upgrade
|
| Interest Expense | -11.27 | -12.45 | -13.33 | -11.59 | -12.81 | -14.05 | Upgrade
|
| Interest & Investment Income | 4.85 | 4.72 | 2.61 | 0.81 | 0.16 | 0.49 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.13 | 0.86 | 0.76 | -0.03 | 0.29 | 0.37 | Upgrade
|
| EBT Excluding Unusual Items | 31.96 | 24.1 | 23.3 | 19.91 | -11.07 | -43.59 | Upgrade
|
| Asset Writedown | - | - | -0.63 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | -12.46 | -9.59 | -16.2 | Upgrade
|
| Other Unusual Items | - | - | - | - | -8.15 | - | Upgrade
|
| Pretax Income | 31.96 | 24.1 | 22.67 | 0.46 | -28.8 | -59.79 | Upgrade
|
| Income Tax Expense | -6.11 | -6.18 | 1.08 | 0.46 | 0.32 | 0.21 | Upgrade
|
| Net Income | 38.07 | 30.28 | 21.59 | 0 | -29.13 | -60 | Upgrade
|
| Net Income to Common | 38.07 | 30.28 | 21.59 | 0 | -29.13 | -60 | Upgrade
|
| Net Income Growth | 147.59% | 40.23% | 1079450.00% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 49 | 49 | 47 | 45 | 41 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 49 | 48 | 45 | 41 | 40 | Upgrade
|
| Shares Change (YoY) | 3.60% | 3.26% | 5.83% | 10.56% | 2.69% | 2.08% | Upgrade
|
| EPS (Basic) | 0.78 | 0.62 | 0.46 | 0.00 | -0.72 | -1.52 | Upgrade
|
| EPS (Diluted) | 0.77 | 0.62 | 0.45 | 0.00 | -0.72 | -1.52 | Upgrade
|
| EPS Growth | 143.51% | 37.78% | 1022625.00% | - | - | - | Upgrade
|
| Free Cash Flow | 31.17 | 38.86 | 26.87 | -15.83 | 20.65 | 0.73 | Upgrade
|
| Free Cash Flow Per Share | 0.63 | 0.79 | 0.56 | -0.35 | 0.51 | 0.02 | Upgrade
|
| Gross Margin | 72.40% | 72.06% | 73.40% | 75.84% | 74.84% | 82.51% | Upgrade
|
| Operating Margin | 16.01% | 13.44% | 14.12% | 13.47% | 0.51% | -13.51% | Upgrade
|
| Profit Margin | 16.36% | 13.14% | 9.16% | 0.00% | -11.51% | -26.65% | Upgrade
|
| Free Cash Flow Margin | 13.39% | 16.86% | 11.40% | -6.94% | 8.16% | 0.32% | Upgrade
|
| EBITDA | 48.67 | 42.49 | 44.78 | 40.56 | 12.6 | -20.37 | Upgrade
|
| EBITDA Margin | 20.91% | 18.44% | 19.01% | 17.79% | 4.98% | -9.05% | Upgrade
|
| D&A For EBITDA | 11.42 | 11.52 | 11.52 | 9.84 | 11.31 | 10.03 | Upgrade
|
| EBIT | 37.25 | 30.97 | 33.27 | 30.72 | 1.29 | -30.4 | Upgrade
|
| EBIT Margin | 16.01% | 13.44% | 14.12% | 13.47% | 0.51% | -13.51% | Upgrade
|
| Effective Tax Rate | - | - | 4.78% | 99.56% | - | - | Upgrade
|
| Revenue as Reported | 232.71 | 230.47 | 235.64 | 228.03 | 253.16 | 225.11 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.